108 related articles for article (PubMed ID: 1616889)
1. Prognostic factors in hormone-resistant progressing cancer of the prostate.
Fosså SD; Dearnaley DP; Law M; Gad J; Newling DW; Tveter K
Ann Oncol; 1992 May; 3(5):361-6. PubMed ID: 1616889
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
3. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
Hernes EH; Linja M; Fosså SD; Visakorpi T; Berner A; Winderen M; Koivisto PA
BJU Int; 2000 Aug; 86(3):240-7. PubMed ID: 10930923
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Vlamis V; Schwartz M; Fossa SD
J Clin Oncol; 1993 Apr; 11(4):607-15. PubMed ID: 7683043
[TBL] [Abstract][Full Text] [Related]
5. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
[TBL] [Abstract][Full Text] [Related]
6. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
Hussain M; Wolf M; Marshall E; Crawford ED; Eisenberger M
J Clin Oncol; 1994 Sep; 12(9):1868-75. PubMed ID: 8083710
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate.
Berry WR; Laszlo J; Cox E; Walker A; Paulson D
Cancer; 1979 Aug; 44(2):763-75. PubMed ID: 476583
[TBL] [Abstract][Full Text] [Related]
10. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors of prostate cancer treated with first-line hormone therapy].
Rigaud J; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
Prog Urol; 2002 Apr; 12(2):232-9. PubMed ID: 12108337
[TBL] [Abstract][Full Text] [Related]
12. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
13. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
Fosså SD; Waehre H; Paus E
Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with advanced stage prostate cancer.
Emrich LJ; Priore RL; Murphy GP; Brady MF
Cancer Res; 1985 Oct; 45(10):5173-9. PubMed ID: 4027993
[TBL] [Abstract][Full Text] [Related]
16. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
Furuya Y; Akimoto S; Akakura K; Igarashi T; Murakami S; Shimazaki J; Ito H
Urol Int; 1998; 60(1):28-32. PubMed ID: 9519418
[TBL] [Abstract][Full Text] [Related]
17. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]